Moloney Securities Asset Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-41,000
| Closed | -$75K | – | 512 |
|
|
2024
Q4 | $75K | Sell |
41,000
-26,200
| -39% | -$47.9K | 0.01% | 444 |
|
|
2024
Q3 | $114K | Sell |
67,200
-85,500
| -56% | -$145K | 0.02% | 455 |
|
|
2024
Q2 | $209K | Sell |
152,700
-12,000
| -7% | -$16.4K | 0.03% | 417 |
|
|
2024
Q1 | $618K | Buy |
+164,700
| New | +$618K | 0.09% | 231 |
|
|
2021
Q1 | – | Sell |
-61,440
| Closed | -$1.59M | – | 424 |
|
|
2020
Q4 | $1.59M | Sell |
61,440
-16,310
| -21% | -$423K | 0.35% | 77 |
|
|
2020
Q3 | $767K | Sell |
77,750
-11,750
| -13% | -$116K | 0.2% | 128 |
|
|
2020
Q2 | $309K | Buy |
89,500
+65,400
| +271% | +$226K | 0.09% | 224 |
|
|
2020
Q1 | $74K | Sell |
24,100
-6,400
| -21% | -$19.7K | 0.03% | 265 |
|
|
2019
Q4 | $157K | Sell |
30,500
-4,500
| -13% | -$23.2K | 0.05% | 330 |
|
|
2019
Q3 | $181K | Buy |
+35,000
| New | +$181K | 0.06% | 302 |
|
|
2019
Q2 | – | Sell |
-121,890
| Closed | -$881K | – | 334 |
|
|
2019
Q1 | $881K | Sell |
121,890
-65,034
| -35% | -$470K | 0.3% | 105 |
|
|
2018
Q4 | $1.38M | Sell |
186,924
-281,037
| -60% | -$2.08M | 0.57% | 44 |
|
|
2018
Q3 | $2.53M | Buy |
467,961
+39,500
| +9% | +$214K | 0.88% | 22 |
|
|
2018
Q2 | $1.52M | Sell |
428,461
-26,210
| -6% | -$93K | 0.58% | 46 |
|
|
2018
Q1 | $932K | Buy |
454,671
+396,271
| +679% | +$812K | 0.38% | 87 |
|
|
2017
Q4 | $154K | Buy |
+58,400
| New | +$154K | 0.06% | 247 |
|
|
2017
Q1 | – | Sell |
-33,600
| Closed | -$128K | – | 248 |
|
|
2016
Q4 | $128K | Buy |
+33,600
| New | +$128K | 0.08% | 210 |
|